
Please try another search
LONDON (Reuters) - Britain's Destiny Pharma (L:DEST), which is developing drugs to target antibiotic-resistant bacterial infections, has raised 15.3 million pounds by listing shares on London's AIM market.
The proceeds will be used to fund a clinical trial for its leading candidate for a drug to prevent post-surgical infection from "superbugs" including MRSA, the company said.
The shares were trading 31 percent higher than the offer price of 157 pence at 207 pence on Monday afternoon.
Destiny Pharma is the second biotech company to list this year, it said, following SkinBio Therapeutics onto AIM.
The company also said on Monday that it had agreed a framework deal with China Medical System (CMS) (HK:0867) to give CMS rights in China and some other Asian countries to develop and commercialise its drugs in return for a 3 million pound equity investment.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.